Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accounts Payables: 2022-2024

Historic Accounts Payables for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $2.6 million.

  • Corvus Pharmaceuticals' Accounts Payables rose 5.39% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 5.39%. This contributed to the annual value of $2.6 million for FY2024, which is 69.31% up from last year.
  • Corvus Pharmaceuticals' Accounts Payables amounted to $2.6 million in FY2024, which was up 69.31% from $1.5 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Accounts Payables registered a high of $2.6 million during FY2024, and its lowest value of $1.5 million during FY2023.
  • Moreover, its 3-year median value for Accounts Payables was $2.0 million (2022), whereas its average is $2.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first dropped by 22.82% in 2023, then spiked by 69.31% in 2024.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Accounts Payables stood at $2.0 million in 2022, then dropped by 22.82% to $1.5 million in 2023, then soared by 69.31% to $2.6 million in 2024.